PL3371152T3 - Kompozycje zawierające inhibitor specyficznej dla lizyny demetylazy-1 mający pierścień pirymidynowy i jego zastosowanie w leczeniu nowotworów - Google Patents
Kompozycje zawierające inhibitor specyficznej dla lizyny demetylazy-1 mający pierścień pirymidynowy i jego zastosowanie w leczeniu nowotworówInfo
- Publication number
- PL3371152T3 PL3371152T3 PL16863111T PL16863111T PL3371152T3 PL 3371152 T3 PL3371152 T3 PL 3371152T3 PL 16863111 T PL16863111 T PL 16863111T PL 16863111 T PL16863111 T PL 16863111T PL 3371152 T3 PL3371152 T3 PL 3371152T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- inhibitor
- compositions
- treatment
- pyrimidine ring
- Prior art date
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title 1
- 239000004472 Lysine Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000000714 pyrimidinyl group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251507P | 2015-11-05 | 2015-11-05 | |
| PCT/US2016/060694 WO2017079670A1 (en) | 2015-11-05 | 2016-11-04 | Compositions comprising an inhibitor of lysine specific demethylase-1 |
| EP16863111.7A EP3371152B1 (en) | 2015-11-05 | 2016-11-04 | Compositions comprising an inhibitor of lysine specific demethylase-1 having a pyrimidine ring and its use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3371152T3 true PL3371152T3 (pl) | 2021-06-28 |
Family
ID=58662888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16863111T PL3371152T3 (pl) | 2015-11-05 | 2016-11-04 | Kompozycje zawierające inhibitor specyficznej dla lizyny demetylazy-1 mający pierścień pirymidynowy i jego zastosowanie w leczeniu nowotworów |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9828358B2 (pl) |
| EP (1) | EP3371152B1 (pl) |
| JP (1) | JP6995043B2 (pl) |
| CN (1) | CN108473442B (pl) |
| AR (1) | AR106612A1 (pl) |
| AU (1) | AU2016349707B2 (pl) |
| CA (1) | CA3004300C (pl) |
| CY (1) | CY1124078T1 (pl) |
| DK (1) | DK3371152T3 (pl) |
| ES (1) | ES2846951T3 (pl) |
| HR (1) | HRP20210144T8 (pl) |
| HU (1) | HUE053449T2 (pl) |
| LT (1) | LT3371152T (pl) |
| MX (2) | MX387607B (pl) |
| PL (1) | PL3371152T3 (pl) |
| PT (1) | PT3371152T (pl) |
| RS (1) | RS61404B1 (pl) |
| SI (1) | SI3371152T1 (pl) |
| SM (1) | SMT202100044T1 (pl) |
| TW (1) | TW201720808A (pl) |
| WO (1) | WO2017079670A1 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE057895T2 (hu) | 2014-05-01 | 2022-06-28 | Celgene Quanticel Res Inc | Lizinspecifikus demetiláz-1 inhibitorai |
| RS61404B1 (sr) | 2015-11-05 | 2021-02-26 | Celgene Quanticel Research Inc | Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primena u lečenju kancera |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| WO2018106984A1 (en) | 2016-12-09 | 2018-06-14 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| SI3661510T1 (sl) | 2017-08-03 | 2025-03-31 | Oryzon Genomics, S.A. | Postopki zdravljenja vedenjskih sprememb |
| US20220151999A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| US20220151998A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| EP3983016A4 (en) * | 2019-06-13 | 2023-06-07 | Celgene Corporation | METHODS OF TREATMENT OF CANCER BY TARGETING COLD TUMORS |
| WO2020257671A1 (en) | 2019-06-20 | 2020-12-24 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| KR20230035569A (ko) * | 2020-06-05 | 2023-03-14 | 셀젠 콴티셀 리서치, 인크. | 전립선암의 치료 방법 |
| ES2919083R1 (es) * | 2020-06-29 | 2022-07-26 | Celgene Quanticel Res Inc | Métodos de tratamiento de cáncer de próstata |
| CA3231846A1 (en) | 2021-04-08 | 2022-10-13 | Tamara Maes | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN119497613A (zh) | 2022-05-09 | 2025-02-21 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 |
| WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| WO2003084936A2 (en) | 2002-04-10 | 2003-10-16 | Orchid Chemicals & Pharmaceuticals Limited | Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological |
| CA2513414A1 (en) * | 2002-04-10 | 2003-10-16 | Orchid Chemicals & Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
| EP1809611A4 (en) * | 2004-10-06 | 2009-11-25 | Nps Pharma Inc | PYRIMIDINONE COMPOUNDS USED AS CALCILYTICS |
| TW201016676A (en) * | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| EP3094627B1 (en) | 2014-01-17 | 2018-08-22 | Novartis AG | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
| HUE057895T2 (hu) * | 2014-05-01 | 2022-06-28 | Celgene Quanticel Res Inc | Lizinspecifikus demetiláz-1 inhibitorai |
| RS61404B1 (sr) * | 2015-11-05 | 2021-02-26 | Celgene Quanticel Research Inc | Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primena u lečenju kancera |
-
2016
- 2016-11-04 RS RS20210094A patent/RS61404B1/sr unknown
- 2016-11-04 MX MX2020004894A patent/MX387607B/es unknown
- 2016-11-04 HU HUE16863111A patent/HUE053449T2/hu unknown
- 2016-11-04 HR HRP20210144TT patent/HRP20210144T8/hr unknown
- 2016-11-04 EP EP16863111.7A patent/EP3371152B1/en active Active
- 2016-11-04 MX MX2018005620A patent/MX373363B/es active IP Right Grant
- 2016-11-04 US US15/344,426 patent/US9828358B2/en active Active
- 2016-11-04 SI SI201631055T patent/SI3371152T1/sl unknown
- 2016-11-04 PT PT168631117T patent/PT3371152T/pt unknown
- 2016-11-04 DK DK16863111.7T patent/DK3371152T3/da active
- 2016-11-04 AU AU2016349707A patent/AU2016349707B2/en not_active Ceased
- 2016-11-04 SM SM20210044T patent/SMT202100044T1/it unknown
- 2016-11-04 WO PCT/US2016/060694 patent/WO2017079670A1/en not_active Ceased
- 2016-11-04 CN CN201680076854.5A patent/CN108473442B/zh active Active
- 2016-11-04 PL PL16863111T patent/PL3371152T3/pl unknown
- 2016-11-04 JP JP2018522953A patent/JP6995043B2/ja active Active
- 2016-11-04 ES ES16863111T patent/ES2846951T3/es active Active
- 2016-11-04 CA CA3004300A patent/CA3004300C/en active Active
- 2016-11-04 LT LTEP16863111.7T patent/LT3371152T/lt unknown
- 2016-11-07 TW TW105136105A patent/TW201720808A/zh unknown
- 2016-11-07 AR ARP160103391A patent/AR106612A1/es unknown
-
2017
- 2017-10-25 US US15/793,512 patent/US10047069B2/en active Active
-
2018
- 2018-07-10 US US16/032,002 patent/US10316016B2/en active Active
-
2019
- 2019-06-10 US US16/436,541 patent/US10703739B2/en active Active
-
2021
- 2021-01-28 CY CY20211100072T patent/CY1124078T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202100044T1 (it) | Composizioni comprendenti un inibitore della demetilasi-1 specifica per la lisina avente un anello pirimidinico e suo uso nel trattamento del cancro | |
| IL272948A (en) | ENPP1 inhibitors and their use for cancer treatment | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| IL248455A0 (en) | igf-1r antibody-drug conjugate and its use for cancer treatment | |
| IL258953A (en) | Dihydroimidazopyrazinone derivatives are useful for the treatment of cancer | |
| GB201511382D0 (en) | Novel compounds and their use in therapy | |
| IL280690A (en) | Pharmaceutical preparations that include DGLA and their use | |
| SMT202500469T1 (it) | Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla | |
| PT4101454T (pt) | Composições para utilização no tratamento da hipertensão | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| ZA201905402B (en) | Compounds and their use in the treatment of schistosomiasis | |
| IL254599A0 (en) | Variants of protoxin-ii and methods of use | |
| GB201514015D0 (en) | Novel pyridazinones and their use in the treatment of cancer | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| PL3341481T3 (pl) | Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne | |
| GB201514018D0 (en) | Novel tricyclic compounds and their use in the treatment of cancer | |
| PL3020794T3 (pl) | Kompozycja środka piorącego i jej zastosowanie | |
| GB201621959D0 (en) | Compositions and their use | |
| GB201621390D0 (en) | Novel compositions having use in therapy | |
| GB201403086D0 (en) | Selection of virus and agent useful in the treatment of cancer | |
| GB201602665D0 (en) | Compositions and their use | |
| GB201600570D0 (en) | Novel compositions having use in therapy |